Lecture Hall General Diabetes | Treatment

Advances in the Treatment of Childhood Diabetes

Available Credits
CE 0.8/0.25
CPME 0.75
ACPE 0.75

William Tamborlane
William Tamborlane, MD, FAAP, FACE
Director of the Childrens Diabetes Program
Yale Pediatrics
Yale School of Medicine
New Haven, CT
System Requirements Method of Participation Disclosure Information

This lecture by William V. Tamborlane, MD describes the special challenges in treating youth with type 1 diabetes mellitus (T1DM), especially with respect to achieving target blood glucose and glycosylated hemoglobin levels and minimizing the risk of severe hypoglycemia. The impact of recent advances in therapy, including rapid and long acting insulin analogs, insulin pumps and continuous glucose monitoring, on the management and clinical outcomes of children and adolescents with T1DM are discussed in detail. The potential for combining these advances towards the development of an artificial pancreas will be presented

Goal and Objective
After participating in this activity, the viewer should be better able to:
1. Understand the pathophysiology of pediatric diabetes.
2. Relate current insulin treatments in light of past methods.
3. Describe newer insulin pump therapies and new technologies such as continuous glucose monitoring systems.
4. Anticipate which children are candidates for insulin pump therapy.

Estimated time to complete this activity is 50 minutes.

Physicians, diabetes educators, and other health care professionals who treat patients with diabetes.
Accreditation and Designation of Credit
The National Association of Nurse Practitioners in Women's Health approves this activity for 0.8 contact hours and 0.25 pharmacological hours.

Release Date: 02/27/2007 Expiration Date: 08/31/2010
Peer Review: on 02/27/2007


The Ohio College of Podiatric Medicine (OCPM) is an approved sponsor of Continuing Podiatric Medical Education through the Council on Podiatric Medical Education (CPME).

The Ohio College of Podiatric Medicine credits this activity for 0.75 credit hour.

Release Date: 02/27/2007 Expiration Date: 12/31/2010
Peer Review: on 02/27/2007


Nova Southeastern University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program has been approved for 0.75 contact hours of General Pharmacy Continuing Education.

Release Date: 01/26/2010 Expiration Date: 10/01/2011
Peer Review: on 10/01/2009


System Requirements
Advances in the Treatment of Childhood Diabetes
Top
A Pentium-III class computer with a minimum of 256MB of system RAM is required to view Online Internet lectures. While a 56Kbps dial-up connection is supported, a Cable or DSL broadband Internet is strongly recommended for optimal video playback. You will need an up-to-date web browser such as Internet Explorer, Mozilla Firefox, or the AOL browser with Java and JavaScript enabled. Some lectures require the use of Internet Explorer to run and will not run with other browsers. Lectures may require the use of helper applications or plug-ins to access the materials. For example, most online lectures/presentations require either Adobe Flash Player or Windows Media Player (both free). To be able to print completion certificates Adobe Acrobat Reader must be installed.
Method of Participation
Advances in the Treatment of Childhood Diabetes
Top
Complete the 4 steps to earn CE/CME credit:
  • Complete and submit the required pre-test
  • View Lecture
  • Complete and submit post-test and program evaluation. Credit will be issued with a passing score of 70% or better.
  • Click Print Certificate.
Disclosure Information
Advances in the Treatment of Childhood Diabetes
Top
It is the policy of PRESENT e-Learning Systems to insure balance, independence, objectivity and scientific rigor in all its individually sponsored or jointly sponsored educational programs. All faculty participating in any PRESENT e-Learning Systems sponsored programs are expected to disclose to the program audience any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing education program. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic. The intent of this policy is not to prevent a speaker with a potential conflict of interest from making a presentation. It is merely intended that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts.
William Tamborlane, MD, FAAP, FACE William V Tamborlane, MD has disclosed that he has received Honorarium/Expenses from Medtronic Diabetes and Novo Nordisk. He has consulted for or advised Medtronic Diabetes and Novo Nordisk